352 related articles for article (PubMed ID: 31394786)
1. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Mueller T; Freystein J; Lucas H; Schmoll HJ
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
[TBL] [Abstract][Full Text] [Related]
2. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C
MAbs; 2016; 8(3):562-73. PubMed ID: 26864324
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
Bessho H; Wong B; Huang D; Tan J; Ong CK; Iwamura M; Hart S; Dangl M; Thomas M; Teh BT
Cancer Invest; 2015; 33(8):378-86. PubMed ID: 26115098
[TBL] [Abstract][Full Text] [Related]
5. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
6. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
8. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Kloepper J; Riedemann L; Amoozgar Z; Seano G; Susek K; Yu V; Dalvie N; Amelung RL; Datta M; Song JW; Askoxylakis V; Taylor JW; Lu-Emerson C; Batista A; Kirkpatrick ND; Jung K; Snuderl M; Muzikansky A; Stubenrauch KG; Krieter O; Wakimoto H; Xu L; Munn LL; Duda DG; Fukumura D; Batchelor TT; Jain RK
Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4476-81. PubMed ID: 27044098
[TBL] [Abstract][Full Text] [Related]
9. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
10. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
11. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
Yeom DH; Lee YS; Ryu I; Lee S; Sung B; Lee HB; Kim D; Ahn JH; Ha E; Choi YS; Lee SH; You WK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383646
[TBL] [Abstract][Full Text] [Related]
12. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT; Lundh von Leithner P; Foxton R; Barathi VA; Cheung CM; Bo Tun SB; Wey YS; Iwata D; Dostalek M; Moelleken J; Stubenrauch KG; Nogoceke E; Widmer G; Strassburger P; Koss MJ; Klein C; Shima DT; Hartmann G
EMBO Mol Med; 2016 Nov; 8(11):1265-1288. PubMed ID: 27742718
[TBL] [Abstract][Full Text] [Related]
13. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.
Goede V; Coutelle O; Neuneier J; Reinacher-Schick A; Schnell R; Koslowsky TC; Weihrauch MR; Cremer B; Kashkar H; Odenthal M; Augustin HG; Schmiegel W; Hallek M; Hacker UT
Br J Cancer; 2010 Oct; 103(9):1407-14. PubMed ID: 20924372
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
Hofmann I; Baum A; Hofmann MH; Trapani F; Reichel-Voda C; Ehrensperger D; Aichinger M; Ebner F; Budano N; Schweifer N; Sykora M; Depla E; Boucneau J; Gschwind A; Kraut N; Hilberg F; Künkele KP
J Pharmacol Exp Ther; 2023 Mar; 384(3):331-342. PubMed ID: 36241203
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
